Imexpharm

Imexpharm Net Debt

The Net Debt of Imexpharm (IMP.VN) as of Oct 26, 2026 is 212.78 B VND. In the previous year, Net Debt was 86.12 B VND — a change of 147.07% (higher).

Net Debt

212.78 BVND

YoY

147.07%

Last updated:

Net Debt of Imexpharm is 2025 212.78 B VND. Net Debt of Imexpharm was 2024 86.12 B VND. It decreases by 147.07% higher compared to the previous year.

The Imexpharm Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2018
-194.72 B VND
Jan 1, 2019
37.58 B VND
Jan 1, 2020
130.93 B VND
Jan 1, 2021
263.79 B VND
Jan 1, 2022
94.98 B VND
Jan 1, 2023
49.42 B VND
Jan 1, 2024
86.12 B VND
Jan 1, 2025
212.78 B VND
The Imexpharm Net Debt history
YEARNet DebtYoY
212.78 BVND+147.07%
86.12 BVND+74.26%
49.42 BVND-47.97%
94.98 BVND-63.99%
263.79 BVND+101.48%
130.93 BVND+248.40%
37.58 BVND-119.30%
-194.72 BVND-32.74%
-289.50 BVND+150.61%
-115.52 BVND-39.65%
-191.41 BVND+5.27%
-181.83 BVND—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm Corp manufactures and trades pharmaceuticals, medicinal chemicals, and botanical products, including antiseptics, traditional medicine, medical equipment, cosmetics, and supplemental food and drinks. The company provides packaging and warehousing services specifically for pharmaceutical storage. It also cultivates medicinal herbs. Imexpharm Corp serves the pharmaceutical industry and healthcare sector through its manufacturing, import, export, and trade operations, targeting businesses requiring medicinal products and services. The company's revenue streams include the sale of manufactured pharmaceuticals, imported and exported goods, and services such as packaging and warehousing. Its customers are businesses in the healthcare sector, including distributors and retailers of pharmaceuticals, medical equipment, and related products. The firm's operations span manufacturing, import, export, and trade, with additional services supporting the pharmaceutical supply chain. Imexpharm Corp's product portfolio covers a wide range of medicinal and health-related items, from antiseptics to supplemental food and drinks. The company's involvement in medicinal herb cultivation supports its production of traditional medicine and herbal-based products. This vertical integration enhances its ability to supply comprehensive solutions to healthcare businesses. Imexpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imexpharm stock

Net Debt of Imexpharm is 212.78 B VND in 2025.

Net Debt of Imexpharm changed from 86.12 B VND to 212.78 B VND, representing a 147.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Imexpharm since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's VND is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Imexpharm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Imexpharm

All Key Metrics — Imexpharm